Digital Therapeutics for Type 2 Diabetes: Incorporating Coaching Support and Validating Digital Monitoring

Fundoiano-Hershcovitz, ‪Yifat; Feniger, Eitan; Dar, Sharon; Ritholz, Marilyn D.; Schorr, Allan B; Goldstein, Pavel

doi:10.1177/19322968211017901

Cited by 2 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies providing evidence on app effectiveness and other patient-reported outcomes were found for mySugr [50,51], Glucose Buddy [51,52], Diabetes:M [53], OneTouch Reveal ® [54], ESYSTA [55], Dario Health [56], and Contour™ Diabetes [57].…”

Section: General Characteristic Of the Appsmentioning

confidence: 99%

Functions of mHealth Diabetes Apps That Enable the Provision of Pharmaceutical Care: Criteria Development and Evaluation of Popular Apps

Sherazi

Laeer

Krutisch³

et al. 2022

IJERPH

View full text Add to dashboard Cite

Personal digital health apps for managing diabetes should include functions that enable the provision of pharmaceutical care services and allow within-app communication with pharmacists and other healthcare providers, thereby improving patient outcomes. The primary aim of this study was to assess the functions of diabetes apps that were relevant to providing pharmaceutical care services (i.e., medication management, adherence, non-pharmacological management, interoperability, and communication). Sixteen criteria related to pharmaceutical care were developed and then used to assess ten popular diabetes apps. The highest numbers of pharmaceutical care criteria were met by the apps Diabetes:M and mySugr (11 criteria); Contour™Diabetes, Dario Health, and OneTouch Reveal® (ten); and DiabetesConnect and ESYSTA (nine); followed by Glucose Buddy (eight), meala (seven), and lumind (three). The most prevalent functions were related to promoting adherence and non-pharmacological management, but most criteria relevant to medication management were lacking. Five apps allowed within-app communication between patients and healthcare professionals (HCPs); however, no app included communication with pharmacists. High-quality diabetes apps are powerful tools to support pharmaceutical care and remotely monitor diabetes patients. Improvements are needed as they often lack many medication management functions, including within-app communication with HCPs (especially pharmacists). To maximize diabetes app use and improve outcomes, app developers should consider including pharmacists alongside other healthcare providers when customizing app designs.

show abstract

Section: General Characteristic Of the Appsmentioning

confidence: 99%

Functions of mHealth Diabetes Apps That Enable the Provision of Pharmaceutical Care: Criteria Development and Evaluation of Popular Apps

Sherazi

Laeer

Krutisch³

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Digital health interventions are a new form of therapy that can complement existing clinical methods to achieve better outcomes, possibly at a lower cost (see, e.g., Shah & Garg, 2015;Kerr et al, 2019;Fagherazzi & Ravaud, 2019;Nkhom et al, 2020;Pal et al, 2018;Quinn et al, 2018;Murray et al, 2018;Kebede et al, 2018;Larbi et al, 2020;Milani et al, 2021;Fundoiano-Hershcovitz, 2021). Research has shown that they can also improve lifestyle decision-making by the patient population (Osborn et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

“…Several authors have concluded that DHIs have a significant role to play in chronic disease management (Kvedar et al, 2016;Patrick et al, 2016;Murray et al, 2016), such as in T2DM (see, e.g., Shah & Garg, 2015;Kerr et al, 2019;Fagherazzi & Ravaud, 2019;Nkhom et al, 2020;Pal et al, 2018;Quinn et al, 2018;Murray et al, 2018;Kebede et al, 2018;Larbi et al, 2020;Milani et al, 2021;Fundoiano-Hershcovitz, 2021), rheumatology (Kataria and Ravindran, 2018;Soloman and Rudin, 2020), cardiovascular diseases (Widmer et al, 2015;Anand et al, 2016;Widmer et al, 2017), COPD , population health (Peiris-John et al, 2020), disability (Jones et al, 2020) and primary care (Brown-Johnson et al, 2021).…”

Section: Benefits and Issues Associated With Dhi In T2dmmentioning

confidence: 99%

“…Additionally, the study aims to put forward policy measures to overcome these obstacles. Several studies (Kerr et al, 2019;Fagherazzi & Ravaud, 2019;Nkhom et al, 2020;Larbi et al, 2020;Milani et al, 2021;Fundoiano-Hershcovitz, 2021) have provided evidence that utilizing digital health interventions (DHIs) for diabetes management can significantly enhance the health outcomes of patients. Conversely, research (Marshall Jr., 2005;Mitchell et al, 2018;Spears et al, 2018;Osborn et al, 2018) has indicated that African Americans with diabetes exhibit lower adherence to medication regimens and face additional risks than other demographic groups.…”

Section: Conclusion Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Policy barriers to the adoption of digital health interventions in the management of chronic type 2 diabetes among African-American adults in the United States

Sagar

View full text Add to dashboard Cite

Digital Therapeutics for Type 2 Diabetes: Incorporating Coaching Support and Validating Digital Monitoring

Cited by 2 publications

References 6 publications

Functions of mHealth Diabetes Apps That Enable the Provision of Pharmaceutical Care: Criteria Development and Evaluation of Popular Apps

Functions of mHealth Diabetes Apps That Enable the Provision of Pharmaceutical Care: Criteria Development and Evaluation of Popular Apps

Policy barriers to the adoption of digital health interventions in the management of chronic type 2 diabetes among African-American adults in the United States

Contact Info

Product

Resources

About